You are here: Industry Insights > atopic dermatitis

News List

Pfizer’s abrocitinib hits endpoints in late-stage atopic dermatitis study pharmatimes
March 23, 2020
Pfizer has revealed that its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, has met its co-primary efficacy endpoints in a Phase III moderate to severe atopic dermatitis trial.
Dermavant sells Tapinarof commercial rights in Japan pharmaceutical-technology
January 19, 2020
Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to sell the development and commercial rights of tapinarof in Japan.
Connect Biopharma Reports Positive Data from Atopic Dermatitis Study americanpharmaceuticalreview
January 09, 2020
Connect Biopharma announced positive topline data from the Phase 1b study of its novel IL-4Rα antibody, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD).
Study Shows Link Between Atopic Dermatitis and Vitiligo drugs
January 02, 2020
Atopic dermatitis (AD) is associated with vitiligo, according to a review and meta-analysis published online December in the Journal of Cosmetic Dermatology.
Sanofi’s Dupixent met study endpoints in children with atopic dermatitis pharmaceutical-technology
August 07, 2019
Sanofi has announced positive top-line, Phase III results for Dupixent (dupilumab) in children aged six to 11 years old with atopic dermatitis.
Pfizer's abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis pharmafile
May 17, 2019
Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that the therapy met all of its co-primary and secondary endpoints in the treatment of moderate to severe atopic dermatitis (AD) in patients a
Sanofi, Regeneron's Dupixent gains expanded approval in US for certain adolescents with atopic dermatitis firstwordpharma
March 12, 2019
Sanofi and Regeneron Pharmaceuticals on Monday announced that the FDA has expanded approval of Dupixent (dupilumab) to include use in adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis that is not adequately controlled with topical
1 in 10 Will Develop Eczema in Their Lifetime drugs
December 04, 2018
About 10 percent of people will suffer from the itchy skin condition known as eczema at some point in their lives, new research shows......
FDA grants priority review status for Dupixent in atopic dermatitis pharmaceutical-technology
November 10, 2018
Sanofi and Regeneron Pharmaceuticals have received priority review status from the US Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis.
Could treating psoriasis in the future be as easy as going online? worldpharmanews
October 09, 2018
For approximately 8 million Americans, visiting a doctor regularly is the key to managing their psoriasis, a chronic inflammatory skin condition characterized by itchy or painful red patches that can appear anywhere on the body.

Previous page 1 2 3 4 Next page